Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

Table 3 mutated genes in tumor samples #1, 3, 4, 5

sample number	number of (shared) affected genes	by mutation affected genes
1,3,4,5	2	MYD88^a, PIM1
1,4,5	2	BCL2^a, ETV6
3,4,5	1	KMT2D
1,3	2	LPHN3, PRDM1
1,4	2	CD79B^a, SOCS1
1,5	2	IRF4, MYC^a
4,5	3	FOXB1, LRP1B^c, HLA-B
1	13	LTF, EPHA5, EP400, SYNE1, BLNK, STAT3^a, FES, SEPT9, POLR3A, DPYD, TFE3^b, CSMD3, FAT1
3	14	KIT^a, MAGI1, TP53^a, ASXL1^a, SETD2^a, IDH2^a, MTRR, PBRM1, BCR, MN1, RNF213, TOP1^a, ATM^a, FANCM^a
4	14	CDKN1B^a, PAX5, FOXO1, MCL1^a, PTPRT, CARD11^c, PPM1D, DST, BCL10, TCL1A, FN1, HSP90AA1^a, NIN, SLCO1B1
5	17	HSP90AB1^a, ARID5B^a, ETS1, ERBB4^a, CCND2^a, HLA-C, ITGB2, EPHA3, BCL6, TBL1XR1, PCBP1, RECQL4, CREBBP, STAT4^a, MLLT3, KEAP1, BTK^c

^aspecific mutations/CNVs/increased expression of these genes qualify for targetable therapies (incl. Preclinical compounds)
^bMutations in these genes may alter pharmacokinetics of drugs (Pharmacogenomics)
^cMutations in these genes are prohibitive for certain targetable therapies [53]

ISSN: 1471-2407